CLINICAL_TRIALS
trial_result
· 2023-10-06
Clinical Trial Update: 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma [Phase 1, Phase 2]
Summary
Phase 1/2 trial of 177Lu-DTPA-omburtamab for recurrent or refractory medulloblastoma in children; study terminated with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Y-mAbs Therapeutics | Conditions: Medulloblastoma, Childhood | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-10-06